Teva Pharmaceutical Industries (TEVJF) Other financing activities (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Other financing activities across 10 years of filings, most recently posting $36.0 million for Q1 2026.

• Quarterly Other financing activities rose 1100.0% year-over-year to $36.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.0 million (up 1775.0% YoY) and the FY2025 annual result came in at $41.0 million, up 612.5% from the prior year.
• Other financing activities declined to $36.0 million in Q1 2026, from $40.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $40.0 million in Q4 2025 and troughed at -$76.0 million in Q3 2023.
• A 5-year average of -$16.2 million and a median of -$4.0 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 4100.0% — and 2026, when it soared 1100.0%.
• Tracing TEVJF's Other financing activities over 5 years: stood at -$3.0 million in 2022, then sank by 2433.33% to -$76.0 million in 2023, then jumped by 114.47% to $11.0 million in 2024, then surged by 263.64% to $40.0 million in 2025, then retreated by 10.0% to $36.0 million in 2026.
• Business Quant data shows TEVJF's Other financing activities at $36.0 million in Q1 2026, $40.0 million in Q4 2025, and -$2.0 million in Q3 2025.